An experiment was planned to visualize the impact of terminal heat stress on yield potentials of late sown mustard cultivars under the changing climatic conditions. A set of fifteen B. juncea genotypes were evaluated at two planting dates during two winter seasons. Late planted genotypes faced heat stress during post anthesis/seed filling stage which negatively influenced the movements of photosynthates to developing sinks thus inhibiting synthetic processes, lowering seed weight and seed yield and may even hamper seed quality. Onset of flowering and siliquing were delayed but the completion of flowering and siliquae formation was earlier in the late planted genotypes. Seed filling was impeded by high temperature in late planting causing ≥50% decline in seed yield. Average accumulated growing degree days (AGDD) for phenological stages were higher in normal sown than the late sown crop. AGDD witnessed an increasing trend for flowering and fruiting behaviour in both the sowing dates. However, 50% flowering in late sown crop took 4 accumulated GDDoC days more. Average heat use efficiency was found to be significantly higher in normal sown genotypes for seed (0.95 kg ha-1 ºC-days-1) and biological (0.53 kg ha-1 ºC-days-1) yield relative to the late sown genotypes for seed (0.50 kg ha-1 ºC-days-1) and biological yield (2.71 kg ha-1 ºC-days-1). Seed yield under late sown condition had positive and significant correlation with siliquing duration (r= 0.600*) and reproductive phase (r= 0.558*) whereas, negative with flowering completion (r= -0.573*) and siliqua initiation (r= -0.519*). Based on the results IAN was the best genotype for delayed sowings.

Sodium/glucose cotransporter-2 (SGLT2) inhibitors have not been assessed extensively for the treatment of hyperglycemia in noncritically ill, hospitalized patients with type 2 diabetes (T2D). In this investigator-initiated, treat-to-target, randomized trial, 250 cardiac surgery patients with T2D were randomly assigned (1:1) to receive dapagliflozin 10 mg daily plus basal-bolus insulin (DAPA group) or basal-bolus insulin alone (INSULIN group) in the early postoperative period. The primary outcome was mean differences between groups in their daily blood glucose (BG) concentrations. The major safety outcomes were the occurrence of severe ketonemia/diabetic ketoacidosis (DKA) and hypoglycemia. All analyses were performed according to the intention-to-treat principle. There were no differences in mean daily BG concentrations (149 vs. 150 mg/dL), mean percentage of readings within the target BG of 70-180 mg/dL (82.7% vs. 82.5%), daily total insulin dose (mean, 39 vs. 40 units/day), number of daily insulin injections (median, 3.9 vs. 4), length of stay (median, 10 vs. 10 days), or hospital complications (21.6% vs. 24.8%) between the DAPA and INSULIN groups. Mean plasma ketone levels were significantly higher in the DAPA group than in the INSULIN group at day 3 (0.71 vs. 0.30 mmol/L) and day 5 (0.42 vs. 0.19 mmol/L) of randomization. Six patients in the DAPA group developed severe ketonemia, but none developed DKA. There were no differences in the proportion of patients with BG <70 mg/dL (9.6% vs. 7.2%) between the treatment groups. Numerically fewer patients in the DAPA group developed acute kidney injury (7.2%) than in the insulin group (12.8%). These findings indicate that dapagliflozin complementary to basal-bolus insulin does not improve glycemia further over and above the basal-bolus in hospitalized cardiac surgery patients with T2D. However, dapagliflozin is safe and does not increase the incidence of DKA or other complications during the hospital stay. Disclosure M. S. Kuchay: Other Relationship; Boehringer-Ingelheim, Novartis India, Sanofi, Novo Nordisk, Intas Pharmaceuticals Ltd., Sun Pharmaceutical Industries Ltd., USV Private Limited, MSD Life Science Foundation. C. Kohli: None. G. Bakshi: None. V. Radhika: None. S. Saheer: None. M. K. Singh: None. S. Mishra: Other Relationship; Abbott, Novo Nordisk, Sanofi, AstraZeneca, Boehringer-Ingelheim, Eli Lilly and Company, Intas Pharmaceuticals Ltd., Sun Pharmaceutical Industries Ltd., Merck Sharp & Dohme Corp., Cipla Inc. P. Khatana: None. M. Mishra: None. P. S: None. P. Kaur: Other Relationship; Abbott, AstraZeneca, Boehringer Ingelheim Inc., Eris Lifesciences Ltd., Novartis India, Sanofi. J. S. Wasir: Other Relationship; Abbott, AstraZeneca, Novartis. H. Kaur: Other Relationship; AstraZeneca, Novo Nordisk, Sanofi, Intas Pharmaceuticals Ltd., Sun Pharmaceutical Industries Ltd. A. Singh: None. R. Jain: Other Relationship; Abbott, AstraZeneca, Lilly Diabetes. Funding Diabetes and Endocrinology Foundation of India